International Stem Cell (ISCO) Retained Earnings (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Retained Earnings of $107.0 million for Q4 2025, up 196.7% year-over-year from $36.1 million in Q4 2024, and up 196.6% quarter-over-quarter from -$110.8 million in Q3 2025.
International Stem Cell (ISCO) Retained Earnings (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Retained Earnings for 16 consecutive years, with $107.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Retained Earnings rose 196.7% year-over-year to $107.0 million; the TTM figure through Dec 2025 stood at $107.0 million (up 196.7% YoY), while the FY2025 annual figure was $107.0 million, up 196.7% from the prior year.
- Retained Earnings climbed to $107.0 million in Q4 2025 per ISCO's latest filing, from -$110.8 million in the prior quarter.
- Across five years, Retained Earnings topped out at $107.0 million in Q4 2025 and bottomed at -$110.8 million in Q2 2025.
- Historically, Retained Earnings has averaged -$12.9 million across 5 years, with a median of -$109.6 million in 2021.
- Annual changes were most pronounced in 2021 — Retained Earnings slumped 205.59% — and 2024, when it soared 196.93%.
- International Stem Cell's Retained Earnings stood at $105.4 million in 2021, then gained by 0.38% to $105.8 million in 2022, then tumbled by 204.41% to -$110.5 million in 2023, then declined by 0.19% to -$110.7 million in 2024, then jumped by 196.7% to $107.0 million in 2025.
- Business Quant data shows ISCO's Retained Earnings at $107.0 million in Q4 2025, -$110.8 million in Q3 2025, and -$110.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | -111.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -111.40 Mn |
| Dec 31, 2025 | 107.03 Mn |
| Sep 30, 2025 | -110.80 Mn |
| Jun 30, 2025 | -110.80 Mn |
| Mar 31, 2025 | 106.84 Mn |
| Dec 31, 2024 | -110.69 Mn |
| Sep 30, 2024 | 106.64 Mn |
| Jun 30, 2024 | 106.54 Mn |
| Mar 31, 2024 | -110.69 Mn |
| Dec 31, 2023 | -110.48 Mn |
| Sep 30, 2023 | -110.02 Mn |
| Jun 30, 2023 | 106.03 Mn |
| Mar 31, 2023 | -110.40 Mn |
| Dec 31, 2022 | 105.81 Mn |
| Sep 30, 2022 | -110.40 Mn |
| Jun 30, 2022 | 105.59 Mn |
| Mar 31, 2022 | 105.50 Mn |
| Dec 31, 2021 | 105.41 Mn |
| Sep 30, 2021 | -109.66 Mn |
| Jun 30, 2021 | -109.50 Mn |